Table 1 Clinical characteristics on admission
Parameters | Normal range | Over all (39) | CT improving at 3 month (31) | CT not improving at 3 month (8) |
|---|---|---|---|---|
Age (years, median and IQR) | ≥ 18 | 62.5 (51.3–71) | 59.2 (50.2–71) | 69.4 (60.2–71.7) |
Sex (female, n and %) | 9 (23.1) | 7 (22.6) | 2 (25) | |
BMI > 25 kg/m2 (n and %) | 27 (69.2) | 21 (67.7) | 6 (75) | |
Active smokers (n and %) | 3 (7.7) | 2 (6.4) | 1 (12.5) | |
Previous smokers (n and %) | 12 (30.8) | 8 (25.8) | 4 (50) | |
Smoking burden (p/y, mean ± SD) | 10.4 ± 16.6 | 7.8 ± 14.9 | 20.7 ± 19.9 | |
Allergies (n and %) | 11 (28.2) | 9 (29) | 2 (33.3) | |
Flu vaccination on adm. (n and %) | 12 (30.8) | 9 (29) | 4 (50) | |
Pneumococcal vaccination on adm. (n and %) | 1 (2.6) | 0 (0) | 1 (12.5) | |
Length of stay (days, median and IQR) | 15 (12–22) | 15 (11–21) | 15.5 (12–28.7) | |
Hypertension (n and %) | 11 (28.2) | 9 (29) | 5 (62.5) | |
Diabetes (n and %) | 5 (12.8) | 4 (12.9) | 1 (12.5) | |
Cardiovascular diseases (n and %) | 7 (17.9) | 5 (16.1) | 2 (33.3) | |
Coronary heart disease (n and %) | 4 (10.2) | 2 (6.4) | 2 (33.3) | |
Chronic respiratory diseases (n and %) | 8 (20.5) | 6 (19.4) | 2 (33.3) | |
COPD (n and %) | 3 (7.7) | 2 (6.4) | 1 (12.5) | |
Asthma (n and %) | 5 (12.8) | 4 (12.9) | 1 (12.5) | |
Chronic kidney disease (n and %) | 3 (7.7) | 2 (6.4) | 1 (12.5) | |
Malignancy (n and %) | 4 (10.2) | 3 (9.7) | 1 (12.5) | |
Intensive care unit admission (n and %) | 10 (25.6) | 9 (29) | 1 (12.5) | |
Invasive mechanical ventilation (n and %) | 7 (17.9) | 6 (19.4) | 1 (12.5) | |
Rehab. after discharge (n and %) | 7 (17.9) | 6 (19.4) | 1 (12.5) | |
Peak PCR (mg/l) (mean ± SD) | 1–5 | 185.7 ± 147.4 | 178.5 ± 137.4 | 213.4 ± 189.6 |
Peak LDH (U/l) (mean ± SD) | < 500 | 653.2 ± 348.5 | 693.4 ± 364.8 | 502.4 ± 240.3 |
Peak leukocytes (G/l) (mean ± SD) | 4.2–10 | 8.9 ± 4.8 | 8.3 ± 3.8 | 11.1 ± 7.5 |
Peak lymphopenia (G/l) (mean ± SD) | 1.5 – 2.5 | 0.7 ± 0.2 | 0.7 ± 0.2 | 0.6 ± 0.3 |
Peak thrombopenia (G/l) (mean ± SD) | 150–400 | 185.5 ± 81.9 | 187.6 ± 72.6 | 177 ± 117 |
Peak d-dimer (mg/l) (mean ± SD) | < 0.5 | 4.8 ± 10 | 5.3 ± 11.5 | 2.9 ± 2.9 |
Lympho. on adm. (G/l) (mean ± SD) | 1.5–2.5 | 0.8 ± 0.3 | 0.9 ± 0.3 | 0.67 ± 0.3 |
Leuko. on adm. (G/l) (mean ± SD) | 4.2–10 | 5.5 ± 2.3 | 5.5 ± 2.3 | 5.5 ± 2.4 |
Thrombo on adm. (G/l) (mean ± SD) | 150–400 | 189.9 ± 74.7 | 190 ± 64.2 | 189.4 ± 112.4 |
PaO2 on adm. (kPa) (mean ± SD) | > 8 | 9.3 ± 1.4 | 9.3 ± 1.5 | 9.2 ± 0.6 |
nt-proBNP on adm. (ng/l) (mean ± SD) | < 450 | 275.7 ± 253.7 | 229.5 ± 219.3 | 488 ± 318.4 |
D-dimer (mg/l) (mean ± SD) | < 0.5 | 1.1 ± 0.8 | 1.2 ± 0.9 | 0.9 ± 0.6 |
Antibiotics (n and %) | 24 (61.5) | 21 (67.7) | 8 (37.5) | |
Hydroxychloroquine (n and %) | 32 (82) | 24 (77.4) | 8 (100) | |
Remdesevir (n and %) | 2 (5.1) | 2 (6.4) | 0 (0) | |
Tocilizumab (n and %) | 4 (10.2) | 4 (12.9) | 0 (0) | |
Lopinavir-Ritonavir (n and %) | 21 (53.8) | 19 (61.3) | 2 (25) | |
ACE-I, ARB treatment (n and %) | 11 (28.2) | 8 (25.8) | 3 (37.5) | |
Anticoag. on adm. (n and %) | 4 (10.2) | 2 (6.4) | 2 (25) | |
Antiplt. on adm. (n and %) | 7 (17.9) | 6 (19.4) | 1 (12.5) | |
GGO on adm (n and %) | 34 (89.5) | 27 (87.1) | 7 (87.5) | |
Consolidations on adm (n and %) | 17 (43.6) | 15 (48.4) | 2 (25) | |
Fibrous bands on adm (n and %) | 28 (71.8) | 22 (71) | 6 (75) |